TIGIT and acute myeloid leukemia: A further study by Hattori et al. (41) confirmed that a high expression of TIGIT in BM samples of AML patients after allo-HCT correlated with poor overall survival (OS) and progression-free survival (PFS) as well as decreased incidence of acute GVHD, indicating a regulatory effect of TIGIT on allo-reactive cells.